Company Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation.
The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015.
Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
| Country | United States |
| Founded | 2009 |
| IPO Date | Oct 4, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Victor Perlroth |
Contact Details
Address: 1200 Page Mill Road Palo Alto, California 94304 United States | |
| Phone | 650 281 0850 |
| Website | kodiak.com |
Stock Details
| Ticker Symbol | KOD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001468748 |
| CUSIP Number | 50015M109 |
| ISIN Number | US50015M1099 |
| Employer ID | 27-0476525 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Victor Perlroth M.D. | Co-Founder, Chairman, Chief Executive Officer and President |
| John A. Borgeson CPA, M.B.A. | Executive Vice President, Chief Financial Officer and Secretary |
| Dr. Dolly S. Chang M.D., M.P.H., Ph.D. | Chief Scientific Officer |
| Dr. Hong Liang Ph.D. | Senior Vice President of Development |
| Dr. Stephen Raillard Ph.D. | Senior Vice President of Chemical Development and Manufacturing |
| Almas Qudrat M.Sc. | Chief Quality Officer |
| Dr. J. Pablo Velazquez-Martin M.D. | Chief Medical Officer |
| Dr. Laurent Ducay Ph.D. | Senior Vice President of Biologics Development and Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 3, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 29, 2025 | SCHEDULE 13G/A | Filing |
| Apr 22, 2025 | ARS | Filing |
| Apr 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |